Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)
Completed
- Conditions
- Scalp Psoriasis
- Registration Number
- NCT01052467
- Lead Sponsor
- LEO Pharma
- Brief Summary
This non-interventional, prospective, non-controlled study of Xamiol® Gel, a fixed combination of calcipotriol and betamethason dipropionate, shall investigate in daily routine the efficacy, tolerability and changes in quality-of-life parameters in patients with scalp psoriasis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 724
Inclusion Criteria
- Patients with scalp psoriasis if a treatment with Xamiol® gel is planned anyway
Exclusion Criteria
- Contraindications of Xamiol® Gel listed in the German package insert
- Pretreatment with Xamiol® within the last 4 weeks
- Systemic treatment of psoriasis
- UV light therapy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Physician's Global Assessment of scalp psoriasis After approximately 4 weeks
- Secondary Outcome Measures
Name Time Method Patient's Quality of Life After approximately 4 weeks
Trial Locations
- Locations (1)
University Clinical Schleswig-Holstein, Campus Kiel
🇩🇪Kiel, Germany